{"id":"NCT01644890","sponsor":"Nippon Kayaku Co., Ltd.","briefTitle":"A Phase III Study of NK105 in Patients With Breast Cancer","officialTitle":"A Multi-national Phase III Clinical Study Comparing NK105 Versus Paclitaxel in Patients With Metastatic or Recurrent Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2016-07","completion":"2017-01","firstPosted":"2012-07-19","resultsPosted":"2019-07-29","lastUpdate":"2019-07-29"},"enrollment":436,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer Nos Metastatic Recurrent"],"interventions":[{"type":"DRUG","name":"NK105","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]}],"arms":[{"label":"NK105","type":"EXPERIMENTAL"},{"label":"Paclitaxel","type":"ACTIVE_COMPARATOR"}],"summary":"To verify the non-inferiority of NK105, a paclitaxel-incorporating micellar nanoparticle, to paclitaxel in terms of the progression-free survival in patients with metastatic or recurrent breast cancer.","primaryOutcome":{"measure":"Progression Free Survival","timeFrame":"Baseline, every 6 weeks of study treatment period, and end of study,","effectByArm":[{"arm":"NK105","deltaMin":8.4,"sd":null},{"arm":"Paclitaxel","deltaMin":8.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"20 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":1},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["30745582"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":34,"n":214},"commonTop":["Alopecia","Peripheral sensory neuropathy","Neutrophil count decreased","White blood cell count decreased","Nausea"]}}